Understanding Donor Islet Cells and Their Clinical Role

For patients living with type 1 diabetes, the loss of insulin-producing beta cells transforms a routine biological function into a constant medical calculus. Blood glucose levels that rise or fall dangerously can lead to complications ranging from neuropathy to coma. While exogenous insulin therapy remains the standard of care, it cannot replicate the real-time responsiveness of a healthy pancreas. Transplantation of donor islet cells offers something fundamentally different: living biological insulin factories that sense glucose and release insulin in precisely the amounts needed. This procedure has enabled thousands of patients to achieve insulin independence, sometimes for years at a time. However, the path from a donated pancreas to a functioning graft inside a recipient involves a complex chain of events, each one critical to success. This article provides a detailed examination of donor islet cells, the matching process that determines compatibility, the immunological barriers that must be overcome, and the emerging technologies that promise to reshape the field.

What Are Donor Islet Cells?

The pancreas, an organ roughly six inches long located behind the stomach, performs two distinct jobs. Its exocrine tissue produces digestive enzymes, while its endocrine tissue—the islets of Langerhans—produces hormones that regulate metabolism. Despite representing only 1 to 2 percent of the total pancreatic mass, islets are densely packed with specialized cells that work in concert to maintain glucose homeostasis. A single human pancreas contains approximately one million islets, each measuring between 50 and 200 micrometers in diameter.

Each islet is a micro-organ containing several cell types with distinct functions:

  • Beta cells constitute 50 to 70 percent of islet cells and are the sole source of insulin in the body. They sense blood glucose levels and release insulin in a biphasic pattern: a rapid first phase within minutes of a meal, followed by a sustained second phase that continues until glucose returns to baseline.
  • Alpha cells produce glucagon, the counter-regulatory hormone that raises blood glucose by stimulating glycogen breakdown in the liver. Healthy alpha cell function is essential for preventing hypoglycemia.
  • Delta cells secrete somatostatin, which acts locally to modulate the release of both insulin and glucagon, providing fine-tuning within the islet microenvironment.
  • PP cells produce pancreatic polypeptide, a hormone involved in appetite regulation and digestive function.

In type 1 diabetes, the immune system mistakenly identifies beta cells as foreign and destroys them through a combination of autoantibodies and cytotoxic T cells. Once 80 to 90 percent of beta cells are lost, blood glucose regulation fails. Patients become dependent on exogenous insulin for survival. Islet transplantation replaces these lost cells with healthy beta cells from a deceased donor, restoring the body's ability to produce insulin in response to glucose fluctuations. The results can be transformative: patients who once lived in constant fear of hypoglycemia can experience stable blood glucose levels and, in many cases, complete freedom from insulin injections.

The Islet Isolation Process

Transplanting an entire pancreas is one option, but it is a major surgical procedure with significant risks. Islet transplantation, by contrast, is a minimally invasive infusion. However, extracting islets from the pancreas is a technically demanding process that must be completed under tight time constraints.

The procedure begins with pancreas recovery. The donor pancreas is surgically removed and transported to a certified islet isolation facility. Cold ischemia time—the time between organ recovery and isolation—must be kept under 8 to 10 hours to maintain islet viability. The pancreas is perfused with a cold preservation solution and shipped in a sterile container.

At the isolation facility, the pancreas undergoes enzymatic digestion. Collagenase and neutral protease are infused through the pancreatic duct to break down the extracellular matrix that holds the islets within the exocrine tissue. This digestion is carefully monitored under a microscope; if it proceeds too far, the islets themselves are damaged, but if it is insufficient, islets remain trapped in the surrounding tissue. The digestion process takes roughly 15 to 30 minutes and is stopped by dilution and cooling once the islets are free.

The resulting digest contains a mixture of islets, exocrine cells, and debris. Purification is achieved using density-gradient centrifugation. The digest is layered onto a gradient of varying density (typically using Ficoll or iodixanol) and spun at high speed. Islets, being less dense than exocrine cells, collect at a specific interface and can be harvested with high purity. Modern purification systems can achieve 80 to 95 percent purity, though some contaminating exocrine tissue is acceptable and may even provide trophic support to the islets.

After purification, the islet preparation undergoes rigorous quality assessment. Technicians count the islets and convert the count to islet equivalents (IEQ), a standardized unit that normalizes for islet size. Viability is assessed using fluorescent dyes that distinguish live from dead cells; a viability of at least 70 percent is typically required. Sterility testing is performed, and a sample is tested for glucose-stimulated insulin secretion to confirm functionality. Only preparations that meet all criteria are released for transplantation.

The entire process from pancreas recovery to final product release takes 6 to 12 hours, and the final product is a cell suspension containing 250,000 to 1,000,000 IEQ, depending on donor characteristics and isolation efficiency. The islets are infused into the recipient almost immediately.

The Critical Matching Process

Matching donor islet cells to a recipient involves a multi-layered compatibility assessment that differs significantly from solid organ transplantation. Because islets are transplanted as a cellular graft, the immune system encounters them in a unique context. The liver, where islets are typically infused, is an immunologically active organ, and the immediate interaction between donor cells and recipient immune cells can determine whether the graft survives or is destroyed. A poor match can lead to rapid rejection, loss of the graft, and sensitization that makes future transplantation more difficult.

ABO Blood Type Compatibility

The most fundamental requirement is ABO compatibility. Donor islets carry blood group antigens on their surface, and the recipient's pre-existing antibodies against incompatible antigens can trigger hyperacute rejection within minutes. This is the same principle that governs blood transfusion and solid organ transplantation. A type O recipient can receive only type O islets, while a type A recipient can receive type A or type O islets. Type B and type AB recipients follow analogous rules. Most transplant centers adhere strictly to ABO compatibility, though a small number of centers have explored ABO-incompatible islet transplantation using plasmapheresis and immunosuppression to reduce antibody levels, similar to protocols used in kidney transplantation.

HLA Matching

The human leukocyte antigen (HLA) system is the second major compatibility factor. HLA molecules are cell-surface proteins that present antigen fragments to T cells, enabling the immune system to distinguish self from non-self. The key loci are HLA-A, HLA-B, and HLA-DR. Each person inherits two copies of each gene (one from each parent), resulting in up to six antigens that can be typed.

Matching these antigens between donor and recipient reduces the risk of T-cell-mediated rejection and improves long-term graft survival. Registry data from the Collaborative Islet Transplant Registry (CITR) show that a higher number of HLA matches correlates with better insulin independence rates. However, HLA matching in islet transplantation is less stringent than for kidney or bone marrow transplantation. Because islet recipients require immunosuppressive drugs in any case, many programs accept a moderate degree of mismatch—typically three or four matches out of six—rather than requiring perfect compatibility.

The rationale is pragmatic. The donor pool for islet isolation is already severely limited. Requiring a perfect HLA match would exclude the majority of potential recipients and would not necessarily improve outcomes enough to justify the increased waiting time. The goal is to strike a balance that minimizes rejection risk while maximizing access to transplantation.

Donor-Recipient Size Matching

Islet dose is expressed as islet equivalents per kilogram of recipient body weight (IEQ/kg). The target dose for achieving insulin independence is at least 5,000 IEQ/kg, though some centers aim for 10,000 IEQ/kg or higher. For a 70-kilogram recipient, 5,000 IEQ/kg translates to 350,000 IEQ from a single donor. However, many recipients require islets from two or even three donors to reach the target dose, particularly if the donors are smaller or the isolation yield is suboptimal.

Donor characteristics that influence islet yield include age, body mass index (BMI), and pancreas health. Donors aged 20 to 50 tend to yield the most islets. Those with a BMI in the overweight range (25 to 30) often have larger pancreases with more islet mass, but donors with obesity (BMI over 35) are associated with reduced islet function and a higher risk of isolation failure. Donors with steatosis (fatty infiltration of the pancreas) are also less ideal. Careful donor selection is essential to maximize the chances of achieving a functional graft.

Recipient Sensitization

Patients who have had previous transplants, blood transfusions, or pregnancies may have pre-formed anti-HLA antibodies. These antibodies are detected through a panel reactive antibody (PRA) test, which measures the percentage of a standard panel of donor antigens that the recipient's antibodies react against. A highly sensitized patient (PRA above 80 percent) has antibodies against a broad range of HLA types, making it difficult to find a compatible donor.

For sensitized recipients, the matching process becomes more complex. The transplant team must identify the specific HLA antigens that the recipient has antibodies against and exclude donors carrying those antigens. Virtual crossmatching—a computer-based prediction of compatibility using HLA typing and antibody specificity data—has become a standard tool for this purpose. In some cases, desensitization protocols using plasmapheresis, intravenous immunoglobulin, or B-cell-depleting agents can reduce antibody levels enough to allow transplantation.

Additional Matching Factors

Beyond the core compatibility factors, several other considerations influence the matching decision:

  • Urgency of need – Patients with brittle diabetes, recurrent severe hypoglycemia, or hypoglycemia unawareness are prioritized. These patients face life-threatening events and have the most to gain from transplantation.
  • Waiting time – Allocation systems consider how long a patient has been on the waiting list, with longer waits increasing priority.
  • Geographic proximity – Islet cold ischemia time is limited to 8 to 10 hours. Donor and recipient must be within a distance that allows transport of the isolated islets to the transplant center within this window. This constraint means that patients near major islet isolation centers have better access.
  • Donor health screening – Donors are tested for infectious diseases (HIV, hepatitis B and C, cytomegalovirus, Epstein-Barr virus), active infections, cancer risk, and metabolic conditions. A donor with a history of type 2 diabetes or impaired glucose tolerance would not be suitable.

Immunosuppression and Rejection Prevention

Even with optimal matching, the recipient's immune system will recognize donor islets as foreign. Preventing rejection requires lifelong immunosuppression, and the regimen used in islet transplantation differs from that used for solid organs. The unique features of islet grafts—they are cellular rather than vascularized, they are infused into the portal vein, and they are susceptible to both alloimmune rejection and recurrent autoimmunity—demand a tailored approach.

The Edmonton Protocol

Before 2000, islet transplantation had limited success, with only about 10 percent of recipients achieving insulin independence. That changed with the introduction of the Edmonton Protocol at the University of Alberta. This regimen combined a steroid-free immunosuppressive protocol with careful patient selection and high-quality islet preparations. The key components were:

  • Sirolimus (rapamycin) – An mTOR inhibitor that blocks T-cell proliferation by interfering with interleukin-2 signaling.
  • Tacrolimus – A calcineurin inhibitor that suppresses cytokine production in T cells.
  • Daclizumab – A monoclonal antibody against the IL-2 receptor alpha chain, used as induction therapy to deplete activated T cells at the time of transplantation.

The Edmonton Protocol achieved insulin independence in over 80 percent of recipients at one year, a dramatic improvement. However, long-term follow-up revealed challenges: islet function declined over time, and many patients experienced side effects from the immunosuppressive drugs, including mouth ulcers, diarrhea, edema, and nephrotoxicity. Subsequent modifications have replaced sirolimus with mycophenolate mofetil in many centers, and basiliximab has replaced daclizumab (which is no longer commercially available). Some centers now use belatacept, a co-stimulation blocker that may have a better renal safety profile.

Encapsulation and Immune Evasion

The need for lifelong immunosuppression is a major barrier to wider adoption of islet transplantation. The drugs increase the risk of infection, malignancy, and organ toxicity, and they are poorly tolerated by some patients. Researchers have long sought ways to protect islets from the immune system without systemic immunosuppression. Encapsulation is the most actively investigated approach.

The principle is straightforward: enclose islets in a semi-permeable membrane that allows glucose and insulin to pass freely but blocks immune cells and large antibodies. Several encapsulation strategies are under development:

  • Macroencapsulation – A larger device, often resembling a flat pouch or disc, that can be placed under the skin or in the peritoneal cavity. The device houses thousands of islets and is designed to be retrievable if needed. The most advanced macroencapsulation device, from ViaCyte (now part of Vertex Pharmaceuticals), has been tested in clinical trials and shown to support islet survival, though the numbers of functional cells have been limited.
  • Microencapsulation – Each islet is individually coated in a thin layer of alginate, a biocompatible polymer derived from seaweed. Microcapsules (typically 300 to 500 micrometers in diameter) provide a high surface-to-volume ratio for efficient diffusion. Early clinical trials have shown that microencapsulated islets can survive without immunosuppression for months, but long-term function remains limited by fibrosis and oxygen supply.
  • Layer-by-layer encapsulation – Nano-scale coatings applied to the islet surface using alternating layers of charged polymers. This approach allows precise control over the thickness and permeability of the coating and minimizes diffusion distance. It is still in preclinical development but offers theoretical advantages in terms of reducing capsule volume and improving nutrient exchange.

The major challenges facing encapsulation are oxygen supply, fibrosis (the foreign body response that coats the capsule with scar tissue), and durability of the coating material. Islets have a high metabolic demand and require oxygen concentrations higher than those found in most implantation sites. Strategies to address this include incorporating oxygen-generating biomaterials or co-encapsulating oxygen carriers. Despite these hurdles, encapsulation remains one of the most promising pathways to a low-risk islet therapy.

Challenges Limiting Broader Application

Despite the successes of islet transplantation, the field faces substantial obstacles that keep it from becoming a mainstream treatment for type 1 diabetes. Understanding these challenges is essential for appreciating where the research is heading.

Donor Shortage

The number of available donor pancreases is far below the clinical need. In the United States, approximately 1.5 million people live with type 1 diabetes, yet fewer than 2,000 deceased donors per year are suitable for islet isolation. Many pancreases are discarded because the donor is too young (under 10 years) or too old (over 60), has a high BMI, has prolonged cold ischemia time, or has underlying health issues such as pancreatitis. The result is a severe supply-demand mismatch that limits transplantation to a small fraction of eligible patients.

This shortage has spurred efforts to find alternative cell sources. If a reliable, unlimited supply of functional islet cells could be produced, the donor shortage would become a historical footnote rather than a defining constraint.

Long-Term Graft Durability

Even when transplantation succeeds, islet function tends to decline over time. Registry data from the Collaborative Islet Transplant Registry indicate that 50 to 70 percent of recipients remain insulin-independent at one year, but that number falls to 30 to 50 percent at five years. By ten years, most patients have resumed some level of insulin use, though they often maintain improved glycemic control compared to pre-transplant levels.

The reasons for this decline are multifactorial. Chronic alloimmune rejection can occur even with immunosuppression. Recurrent autoimmunity can target the transplanted beta cells. Immunosuppressive drugs, particularly calcineurin inhibitors like tacrolimus, have direct toxic effects on beta cells and can impair insulin secretion. The high metabolic demand placed on a limited islet mass can lead to beta-cell exhaustion and apoptosis. And the liver environment, where islets are infused, has relatively low oxygen tension, which may contribute to long-term graft loss. Improving durability requires addressing all of these factors simultaneously.

Future Directions and Emerging Technologies

Several converging lines of research promise to overcome the limitations of donor islet transplantation and potentially transform the treatment of type 1 diabetes.

Stem Cell-Derived Islets

The most exciting development in the field is the ability to generate insulin-producing beta cells from pluripotent stem cells. In 2014, researchers at Harvard University led by Douglas Melton published a landmark study showing that human embryonic stem cells could be guided through a series of differentiation steps to become functional beta cells that secreted insulin in response to glucose. The protocol recapitulated the normal developmental stages of pancreatic formation, resulting in cells that expressed key beta-cell markers and exhibited glucose-stimulated insulin secretion in vitro and in vivo.

Since then, several companies have advanced stem cell-derived islets toward clinical use. Vertex Pharmaceuticals has initiated clinical trials with VX-880, a product derived from allogeneic stem cells that are differentiated into fully mature islet cells. Early results have been remarkable: the first patient treated achieved insulin independence after a single infusion, with robust C-peptide production and excellent glycemic control. While the patient required immunosuppression, the results provide proof of concept that stem cell-derived islets can function in humans.

Vertex is also developing VX-264, which combines stem cell-derived islets with an encapsulation device to eliminate the need for immunosuppression. This product is in earlier-stage clinical trials. If successful, it could represent a transformative therapy available to any patient with type 1 diabetes, regardless of donor availability.

The advantages of stem cell-derived islets are significant. They can be produced in unlimited quantities with consistent quality. They can be engineered to reduce or eliminate immunogenicity. And they can be standardized to ensure that every dose contains a defined number of functional cells. The challenge remains demonstrating long-term safety and efficacy, particularly regarding the risk of teratoma formation (from residual undifferentiated cells) and the durability of function.

Gene Editing and Universal Donor Cells

CRISPR-Cas9 and other gene-editing tools are being applied to both donor islets and stem cell-derived islets to reduce immunogenicity. The goal is to create universal donor cells that can be transplanted into any recipient without triggering an immune response. Several approaches are under investigation:

  • Knockout of HLA molecules – Eliminating HLA class I and class II molecules prevents T-cell recognition. However, this also makes the cells vulnerable to natural killer (NK) cells, which recognize cells lacking HLA. Additional engineering to express NK-cell inhibitory ligands is needed.
  • Expression of immune cloaking molecules – CD47, a cell-surface protein that signals "don't eat me" to macrophages, can be overexpressed to protect the graft from innate immune destruction.
  • Insertion of protective transgenes – Genes that confer resistance to inflammatory cytokines (such as IL-1 receptor antagonist or anti-apoptotic proteins) can be introduced to help islets survive the hostile transplant environment.
  • Hypoimmune islets – Some groups have engineered islets that simultaneously knock out HLA class I and II, express HLA-E (which inhibits NK cells), and overexpress CD47. In animal models, these hypoimmune islets survive for months without immunosuppression.

The combination of stem cell technology and gene editing holds the promise of creating off-the-shelf, universal donor islets that can be transplanted into any patient without rejection. This would eliminate both the donor shortage and the need for immunosuppression, solving the two biggest problems in the field.

Alternative Transplant Sites

The liver has been the standard site for islet infusion since the development of the Edmonton Protocol. The portal vein is accessible via a minimally invasive catheter procedure, and the liver provides a supportive environment for islet engraftment. However, the liver is far from ideal. Oxygen tension in the liver sinusoids is relatively low, which can contribute to islet hypoxia and cell death. The liver also exposes islets to high concentrations of immunosuppressive drugs and to the first-pass metabolism of oral medications. Biopsy of the graft is difficult, and retrieval of a failing graft is essentially impossible.

Researchers are exploring alternative transplant sites that might provide better conditions for islet survival and function:

  • The omentum – The omentum, a fatty membrane in the abdomen, has emerged as a leading candidate. It is highly vascularized, can be accessed laparoscopically, and allows for retrieval if needed. Islets can be seeded onto a biodegradable scaffold and placed onto the omentum, where they engraft and become vascularized. Clinical trials using the omental site have shown promising results.
  • The subcutaneous space – Subcutaneous implantation is the least invasive option, but the site has limited blood supply and is prone to fibrosis. Researchers are developing approaches to prevascularize the site using growth factors or temporary implants before islet transplantation.
  • Anterior chamber of the eye – The anterior chamber of the eye is an immune-privileged site with high oxygen tension and easy visual monitoring of the graft. Islets transplanted into the anterior chamber can be observed non-invasively using microscopy, providing a window into graft function. This approach is still experimental but offers unique advantages for research and potentially for clinical use.
  • Bone marrow – The bone marrow is another immune-privileged site that has been used experimentally. Islets infused into the bone marrow have shown engraftment and function in animal models.

The ideal transplant site would provide high oxygen tension, easy access for implantation and monitoring, protection from immune attack, and the ability to retrieve the graft if needed. No single site currently meets all these criteria, but the omentum appears closest to clinical adoption.

Clinical Outcomes and What Patients Can Expect

For patients considering islet transplantation, realistic expectations are essential. The procedure does not cure type 1 diabetes, but it can dramatically improve glycemic control and quality of life. The best outcomes are seen in patients who receive an adequate islet dose (at least 5,000 IEQ/kg), have good HLA matching, and adhere to their immunosuppressive regimen.

The primary goal of islet transplantation is to restore hypoglycemia awareness and prevent severe hypoglycemic events. Even in patients who do not achieve complete insulin independence, most experience a significant reduction in hypoglycemia frequency and severity. Glycated hemoglobin (HbA1c) levels typically improve, and patients report improved quality of life, reduced diabetes-related distress, and greater freedom in daily activities.

However, islet transplantation is not without risks. The infusion procedure can cause bleeding, portal vein thrombosis, and elevation of liver enzymes. Immunosuppression carries risks of infection, malignancy, and drug-specific side effects. And the long-term durability of the graft remains limited, with most patients eventually resuming some insulin use. For these reasons, islet transplantation is currently reserved for patients with type 1 diabetes who have recurrent severe hypoglycemia or hypoglycemia unawareness despite optimized medical management.

Conclusion

Donor islet cell transplantation represents one of the most significant advances in the treatment of type 1 diabetes in the past two decades. The procedure has restored insulin independence and dramatically improved the lives of thousands of patients. The matching process—encompassing blood type, HLA compatibility, islet dose, and recipient sensitization—is a carefully calibrated system designed to maximize graft survival within the constraints of a severely limited donor pool. Yet the current therapy remains a bridge rather than a destination. The reliance on deceased donors and the need for lifelong immunosuppression limit its application to a small fraction of eligible patients.

The future of islet transplantation lies in three converging technologies: stem cell biology, gene editing, and encapsulation. The ability to generate unlimited quantities of functional islet cells from stem cells, combined with genetic engineering to render them invisible to the immune system, could produce an off-the-shelf product available to any patient without the need for immunosuppression. Clinical trials are already underway, and early results are promising. While challenges remain—particularly regarding long-term durability and safety—the trajectory is clear. The day may soon arrive when a reliable, immune-evasive islet product can be given to any patient with type 1 diabetes, transforming the disease from a lifelong burden into a manageable condition.

For further reading, the National Institute of Diabetes and Digestive and Kidney Diseases provides comprehensive patient information. The International Islet Transplant Registry tracks global outcomes and clinical data. Current clinical trials can be explored through ClinicalTrials.gov. For those interested in stem cell research, the JDRF offers updates on the latest developments in beta-cell replacement therapy.